在磺脲类联合二甲双胍控制不佳的2型糖尿病患者中,艾塞那肽联合吡格列酮与基础/餐时胰岛素治疗的比较:卡塔尔研究
卡塔尔研究随机纳入231例磺脲类联合二甲双胍控制不佳(HbA1c>7.5%,58 mmol/mol)的2型糖尿病患者,比较吡格列酮联合每周一次艾塞那肽与基础加餐时胰岛素治疗。平均随访12个月,联合治疗组HbA1c从基线10.0±0.6%降至6.1±0.1%,胰岛素组为7.1±0.1%;胰岛素组体重增加和低血糖发生率均显著高于联合治疗组。
要点
- 联合治疗组HbA1c降幅大于胰岛素组,且不受性别、种族、BMI或基线HbA1c影响。
- 胰岛素组体重增加显著多于联合治疗组,低血糖发生率约为联合治疗组的3倍。
- 艾塞那肽联合吡格列酮在磺脲类联合二甲双胍控制不佳的2型糖尿病患者中是非常有效且安全的治疗选择。
核心结论
- 艾塞那肽联合吡格列酮治疗在长期磺脲类联合二甲双胍控制不佳的2型糖尿病患者中是非常有效且安全的治疗选择。
研究设计与样本
- 卡塔尔研究为随机对照研究,纳入231例磺脲类联合二甲双胍控制不佳(HbA1c>7.5%,58 mmol/mol)的2型糖尿病患者。
- 患者随机接受吡格列酮联合每周一次艾塞那肽(联合治疗)或基础加餐时胰岛素(胰岛素治疗),目标HbA1c<7.0%(53 mmol/mol)。
主要发现
- 平均随访12个月,联合治疗组HbA1c从基线10.0±0.6%(86±5.2 mmol/mol)降至6.1±0.1%(43±0.7 mmol/mol)。
- 胰岛素治疗组HbA1c为7.1±0.1%(54±0.8 mmol/mol)。
- 联合治疗降低HbA1c的疗效不受性别、种族、BMI或基线HbA1c影响。
- 胰岛素治疗组体重增加显著多于联合治疗组。
- 胰岛素治疗组低血糖发生率约为联合治疗组的3倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. RESEARCH DESIGN AND METHODS: The study randomized 231 patients with poorly controlled (HbA1c >7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive 1) pioglitazone plus weekly exenatide (combination therapy) or 2) basal plus prandial insulin (insulin therapy) to maintain HbA1c <7.0% (53 mmol/mol). RESULTS: After a mean follow-up of 12 months, combination therapy caused a robust decrease in HbA1c from 10.0 ± 0.6% (86 ± 5.2 mmol/mol) at baseline to 6.1 ± 0.1% (43 ± 0.7 mmol/mol) compared with 7.1 ± 0.1% (54 ± 0.8 mmol/mol) in subjects receiving insulin therapy. Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, BMI, or baseline HbA1c. Subjects in the insulin therapy group experienced significantly greater weight gain and a threefold higher rate of hypoglycemia than patients in the combination therapy group. CONCLUSIONS: Combination exenatide/pioglitazone therapy is a very effective and safe therapeutic option in patients with long-standing poorly controlled T2DM on metformin plus a sulfonylurea.
引用
- Abdul-Ghani M, Migahid O, Megahed A, et al. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care. 2017. PMID: 28096223. doi:10.2337/dc16-1738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。